The Community Guide

- gsearch

Search Results

Narrow Results:

2022 1
2021 1
2020 2
2012 1

2019-nCoV Vaccine mRNA-1273 1
Adolescent 1
Adult 1
Child 1
Coronavirus Infections/prevention & control 2
Coronavirus Infections/prevention &control 1
COVID-19 1
COVID-19 Vaccines 3
Immunization, Secondary 2
Meningococcal Vaccines 1
Pandemics 2
Vaccination 4
Viral Vaccines 2

GlaxoSmithKline. 1
Moderna (firm) 4

Presentation 4

Conference Publications 4

1 - 5 of 5 Results

Refine Results

Refine Results:

Overview of Moderna’s COVID-19 Vaccine (mRNA-1273)

CITE Title : Overview of Moderna’s COVID-19 Vaccine (mRNA-1273) Personal Author(s) : Miller, Jacqueline M. Corporate Authors(s) : Moderna (firm) Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2020 December 19-20, 2020 : Atlanta, GA) Published Date : December 19, 2020 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/105478 Miller, Jacqueline M. (2020). Overview of Moderna’s COVID-19 Vaccine (mRNA-1273). 2000212(0100102). Miller, Jacqueline M. "Overview of Moderna’s COVID-19 Vaccine (mRNA-1273)" 2000212, no. 0100102 (2020) Miller, Jacqueline M. "Overview of Moderna’s COVID-19 Vaccine (mRNA-1273)" vol. 2000212, no. 0100102, 2020 Export RIS Citation Information.

:

Miller, Jacqueline M.

December 19, 2020 | ACIP meeting COVID-19 Vaccines

:

02-COVID-Miller-508.pdf
mRNA-1273 clinical development program

CITE Title : mRNA-1273 clinical development program Personal Author(s) : Miller, Jacqueline M. Corporate Authors(s) : Moderna (firm) Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2020 August 26 : Atlanta, GA) Published Date : August 26, 2020 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/93436 Miller, Jacqueline M. (2020). mRNA-1273 clinical development program. 2000204(000002). Miller, Jacqueline M. "mRNA-1273 clinical development program" 2000204, no. 000002 (2020) Miller, Jacqueline M. "mRNA-1273 clinical development program" vol. 2000204, no. 000002, 2020 Export RIS Citation Information.

:

Miller, Jacqueline M.

August 26, 2020 | ACIP meeting COVID-19 Vaccines

:

COVID-02-Miller-508.pdf
Booster doses of Moderna COVID-19 vaccines in adults, adolescents & children

CITE Title : Booster doses of Moderna COVID-19 vaccines in adults, adolescents & children Personal Author(s) : Miller, Jacqueline M. Corporate Authors(s) : Moderna (firm) Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2022 September 1-2 : Atlanta, GA) Published Date : September 1, 2022 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/120825 Miller, Jacqueline M. (2022). Booster doses of Moderna COVID-19 vaccines in adults, adolescents & children. 202211(101006). Miller, Jacqueline M. "Booster doses of Moderna COVID-19 vaccines in adults, adolescents & children" 202211, no. 101006 (2022) Miller, Jacqueline M. "Booster doses of Moderna COVID-19 vaccines in adults, adolescents & children" vol. 202211, no. 101006, 2022 Export RIS Citation Information.

:

Miller, Jacqueline M.

September 1, 2022 | ACIP meeting COVID-19 Vaccines

:

06-COVID-Miller-508.pdf
MenHibrix® (Meningococcal groups C and Y and Haemophilus B tetanus toxoid conjugate vaccine) : product and clinical data overview

CITE Title : MenHibrix® (Meningococcal groups C and Y and Haemophilus B tetanus toxoid conjugate vaccine) : product and clinical data overview Personal Author(s) : Miller, Jacqueline M. Corporate Authors(s) : GlaxoSmithKline. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2012 October 24-25 : Atlanta, GA) Published Date : October 24, 2012 Series : ACIP meeting Meningococcal Vaccines URL : https://stacks.cdc.gov/view/cdc/77918 Miller, Jacqueline M. (2012). MenHibrix® (Meningococcal groups C and Y and Haemophilus B tetanus toxoid conjugate vaccine) : product and clinical data overview. 201203(010302). Miller, Jacqueline M. "MenHibrix® (Meningococcal groups C and Y and Haemophilus B tetanus toxoid conjugate vaccine) : product and clinical data overview" 201203, no. 010302 (2012) Miller, Jacqueline M. "MenHibrix® (Meningococcal groups C and Y and Haemophilus B tetanus toxoid conjugate vaccine) : product and clinical data overview" vol. 201203, no. 010302, 2012 Export RIS Citation Information.

:

Miller, Jacqueline M.

October 24, 2012 | ACIP meeting Meningococcal Vaccines

:

02-MCV-Miller.pdf
Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine

CITE Title : Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine Personal Author(s) : Miller, Jacqueline M. Corporate Authors(s) : Moderna (firm) Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110915 Miller, Jacqueline M. (2021). Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine. 202113(120203). Miller, Jacqueline M. "Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine" 202113, no. 120203 (2021) Miller, Jacqueline M. "Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine" vol. 202113, no. 120203, 2021 Export RIS Citation Information.

:

Miller, Jacqueline M.

October 21, 2021 | ACIP meeting COVID-19 Vaccines

:

02-COVID-Miller-508.pdf